The Yafo China-Japan-US Business Exchange Dinner Was Successfully Held in San Francisco

Jointly organized by Yafo Capital and Renexes, and sponsored by CHBD, Maxhealth Pharmaceuticals, and Dongyu Consulting, the JPM China-US-Japan Exchange Dinner (East Meets West JPM Mixing Dinner) successfully concluded on January 15, 2020, in San Francisco, USA! A total of 185 participants attended, all of whom were executives from Chinese (50 pharmaceutical companies), Japanese (20 pharmaceutical companies), U.S., European, and other overseas biotechnology companies (80 companies), publicly listed pharmaceutical companies, investment funds, and other institutions.

The dinner invited distinguished guests including Adam Muzikant, Senior Vice President of Yafo client U.S. Flexion Therapeutics; Hardy Kagimoto, CEO of Helios, Japan's second-largest biotech company; Jonathan Wang, President of Inmagene; Wang Kui, Secretary General of CHBD; and Tony Miao, CEO of Maxhealth (Meian Pharmaceuticals), who shared in-depth insights and cooperation cases regarding cross-border transactions in China, Japan, and the U.S.

We welcome more institutions and leaders in the pharmaceutical industry to participate in and support future Yafo series events, jointly promoting the development of the Chinese pharmaceutical industry and expanding China-foreign transaction opportunities.

Event Announcement:

- Access China生物医药论坛 （2020年6月，美国2020BIO大会，圣地亚哥）Investment & BD Forum @BIO International Convention (June 2020, San Diego)

- Access China线上路演及一对一@Bio Europe大会 (2020年3月，巴黎) Virtual ACCESS CHINA Program at Bio Europe (March 2020, Paris)

- The 15th China Pharmaceutical and Medical Technology Business Development Summit Forum (September 2020, Qingdao, China)

For event participation and cooperation, please contact: Li Qi, qli@yafocapital.com, +86-13621979227

About Yafo Global Healthcare

Yafo Global Healthcare (Yafo Life Science) is the healthcare and wellness division under Yafo Capital. We focus on helping overseas pharmaceutical and medical device companies with a 'China perspective' with financing, licensing, and strategic cooperation in China; as well as providing Chinese medical enterprises with overseas market financing and bi-directional market licensing opportunities. We are committed to being a bridge connecting global medical technologies with the Chinese market and capital. Currently, our reach covers eight countries with the strongest medical innovation capabilities, including Israel, the U.S., Switzerland, and Japan. Yafo Global Healthcare focuses on the following services:

1. Sell-side Investment Banking: Assisting advanced medical technology companies, both domestic and international, with financing, mergers and acquisitions, and product licensing in China and overseas;

2. Buy-side Advisory Services: Providing Chinese medical enterprises with overseas market consultation, identifying overseas investment or acquisition targets, and assisting in commercial licensing collaborations for pharmaceuticals and medical devices;

3. Fund Investment: Establishing private equity funds with strategic partners to invest in and introduce mature overseas medical technologies and projects.